Table 1 Impact of expression levels on survival by the different demographic and clinicopathologic factors with colorectal cancer

Overall survival

 ATG4B

Low

63 (53.4)

1.00

1.00

High

55 (46.6)

3.13(1.75–5.59)

< 0.001

5.71(3.04–10.70)

< 0.001

 Phospho-ATG4B

Low

82 (69.5)

1.00

1.00

High

36 (30.5)

3.04(1.75–5.26)

< 0.001

2.50(1.34–4.65)

0.004

ATG4B (L), p-ATG4B (L)

48 (40.7)

1.00

1.00

ATG4B (H), p-ATG4B (L)

34 (28,8)

1.04 (0.58–1.87)

0.907^a

2.25 (1.04–4.85)

0.039^c

ATG4B (L), p-ATG4B (H)

15 (12.7)

0.81 (0.34–1.90)

0.622^a

1.80 (0.66–4.93)

0.251^c

ATG4B (H), p-ATG4B (H)

21 (17.8)

5.74 (3.18-10.338)

< 0.001 ^a

8.83 (4.13–18.90)

< 0.001 ^c

Disease-free survival

 ATG4B

Low

63 (53.4)

1.00

1.00

High

55 (46.6)

2.32(1.37–3.91)

0.002

5.08(2.79–9.22)

< 0.001

 p-ATG4B

Low

82 (69.5)

1.00

1.00

High

36 (30.5)

2.89(1.73–4.84)

< 0.001

2.07(1.18–3.63)

0.011

ATG4B (L), p-ATG4B (L)

48 (40.7)

1.00

1.00

ATG4B (H), p-ATG4B (L)

34 (28,8)

0.82 (0.46–1.46)

0.502^a

1.50 (0.75–3.01)

0.249^c

ATG4B (L), p-ATG4B (H)

15 (12.7)

0.87 (0.40–1.92)

0.733^a

1.54 (0.63–3.75)

0.341^c

ATG4B (H), p-ATG4B (H)

21 (17.8)

5.18 (2.95–9.11)

< 0.001 ^a

6.50 (3.29–12.84)

< 0.001 ^c